Sev­en years in the mak­ing, Seat­tle Ge­net­ics picks up ear­ly op­tion on Gen­mab's ADC ef­fort

Sev­en years af­ter Copen­hagen-based Gen­mab inked a col­lab­o­ra­tion deal with Seat­tle Ge­net­ics, the US biotech has de­cid­ed to opt-in on a de­vel­op­ment part­ner­ship.

The pact struck in 2010 gave Gen­mab rights to Seat­tle Ge­net­ics an­ti­body-drug con­ju­gate tech so it could work on a new ap­proach for its Hu­Max-TF an­ti­body tar­get­ing the tis­sue fac­tor anti­gen. A year lat­er they struck a deal giv­ing Seat­tle Ge­net­ics an opt-in on ti­so­tum­ab ve­dotin, now in sev­er­al Phase I/II stud­ies for sol­id tu­mors, in­clud­ing re­cur­rent cer­vi­cal can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER